DC Field | Value | Language |
---|---|---|
dc.contributor.author | S N Yoon | - |
dc.contributor.author | S A Roh | - |
dc.contributor.author | D H Cho | - |
dc.contributor.author | M B Kim | - |
dc.contributor.author | Y L Hyun | - |
dc.contributor.author | S Ro | - |
dc.contributor.author | B S Kim | - |
dc.contributor.author | Seon-Young Kim | - |
dc.contributor.author | Yong Sung Kim | - |
dc.contributor.author | J C Kim | - |
dc.date.accessioned | 2017-04-19T09:19:31Z | - |
dc.date.available | 2017-04-19T09:19:31Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 0172-6390 | - |
dc.identifier.uri | https://oak.kribb.re.kr/handle/201005/9698 | - |
dc.description.abstract | BACKGROUND/AIMS: This study was performed to determine the efficacy of histone deacetylase inhibitors in gastric cancer, together with other established regimens. METHODOLOGY: The chemosensitivities of 93 gastric cancer patients to established drugs, and three histone deacetylase inhibitors (SAHA, PXD101, and a novel candidate, CG-2) were evaluated using the histoculture drug response assay. RESULTS: Tumor growth inhibition rates were the highest with cisplatin, followed by PXD101, taxol, docetaxel, and TS-1, in descending order. The response rates were 41.9-68.8%, and 37.6-47.3%, respectively, at an inhibition rate cutoff value of 30%. Synergistic activity was evident with most combinations of established drugs and histone deacetylase inhibitors. Diffuse- or mixed-type carcinomas on Lauren classification were closely associated with increased chemosensitivity to TS-1 (p = 0.044). Node-positive and "other than tubular type" tumors on WHO classification were chemosensitive to cisplatin (p = 0.011 and 0.014, respectively). CG-2 chemosensitivity was markedly associated with low preoperative CA72-4 level (≤4 U/ml) (p = 0.046). CONCLUSIONS: This in vitro chemosensitivity assay validates the comparable chemo-response of gastric cancers to histone deacetylase inhibitors and established drugs, indicating considerable therapeutic efficacy of these agents. Additionally, a number of clinicopathological parameters are significantly associated with specific regimens. | - |
dc.publisher | Hge Update Medical Publishing Sa | ko |
dc.title | In vitro chemosensitivity of gastric adenocarcinomas to histone deacetylase inhibitors, compared to established drugs | - |
dc.title.alternative | In vitro chemosensitivity of gastric adenocarcinomas to histone deacetylase inhibitors, compared to established drugs | - |
dc.type | Article | - |
dc.citation.title | Hepato-Gastroenterology | - |
dc.citation.number | 99 | - |
dc.citation.endPage | 662 | - |
dc.citation.startPage | 657 | - |
dc.citation.volume | 57 | - |
dc.contributor.affiliatedAuthor | Seon-Young Kim | - |
dc.contributor.affiliatedAuthor | Yong Sung Kim | - |
dc.contributor.alternativeName | 윤상남 | - |
dc.contributor.alternativeName | 노선애 | - |
dc.contributor.alternativeName | 조동형 | - |
dc.contributor.alternativeName | 김문보 | - |
dc.contributor.alternativeName | 현영란 | - |
dc.contributor.alternativeName | 노승구 | - |
dc.contributor.alternativeName | 김병식 | - |
dc.contributor.alternativeName | 김선영 | - |
dc.contributor.alternativeName | 김용성 | - |
dc.contributor.alternativeName | 김진천 | - |
dc.identifier.bibliographicCitation | Hepato-Gastroenterology, vol. 57, no. 99, pp. 657-662 | - |
dc.subject.keyword | Chemosensitivity | - |
dc.subject.keyword | Gastric adenocarcinomas | - |
dc.subject.keyword | Histoculture drug response assay (HDRA) | - |
dc.subject.keyword | Histone deacetylase inhibitor | - |
dc.subject.local | Chemosensitivity | - |
dc.subject.local | chemosensitivity | - |
dc.subject.local | Gastric adenocarcinoma | - |
dc.subject.local | Gastric adenocarcinomas | - |
dc.subject.local | Histoculture drug response assay | - |
dc.subject.local | Histoculture drug response assay (HDRA) | - |
dc.subject.local | Histone deacetylase inhibitor | - |
dc.subject.local | histone deacetylase inhibitor | - |
dc.description.journalClass | N | - |
There are no files associated with this item.
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.